PHARMO

What PHARMO does

PHARMO Institute is a Dutch real-world evidence (RWE) research organization that has analyzed linked healthcare data since 1999 to support pharmaceutical companies, regulatory authorities, healthcare payers, and providers. The firm maintains direct access to an integrated Dutch healthcare database network spanning 1,400 general practitioners, hospitals, clinical laboratories, community and hospital pharmacies, and specialized registries (pathology, cancer, perinatal care), covering 14 million anonymized patients and 250 million person-years of longitudinal data, linked through validated algorithms.

The company's service portfolio includes post-authorization safety and efficacy studies (PASS, PAES), drug utilization studies, incidence and prevalence research, comparative effectiveness studies with synthetic control arms, healthcare resource utilization and cost-of-illness analyses, and AI-driven patient finding, classification, and disease progression analysis. PHARMO operates as a certified research organization under ENCePP Guide on Methodological Standards, ENCePP Code of Conduct, and EMA Good Pharmacovigilance Practice guidelines, and is a founding member of the SIGMA Consortium — an alliance providing access to 10 of the top 15 secondary databases used in European PASS studies — alongside memberships in ENCePP, VAC4EU, and EU PPV.

PHARMO generates revenue through project-based professional services contracts with enterprise clients in the pharmaceutical, regulatory, payer, and provider segments, with engagement coordinated through its parent organization Lumanity, a global health sciences consulting firm that integrated PHARMO into its real-world evidence capabilities in 2024. Pricing is not publicly disclosed and is negotiated on a per-project basis reflecting study complexity, scope, and duration.

Name

PHARMO

Legal name

PHARMO Institute

Website

https://pharmo.nl

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

PHARMO Institute is a Dutch real-world evidence research firm, operating since 1999, that delivers post-authorization safety studies and other observational research using linked Dutch healthcare databases covering 14 million patients, serving pharmaceutical companies, regulators, payers, and providers.

Ownership category

akta.pro rank

Product category

Real-World Evidence / Pharmacoepidemiology Research Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH)

Keywords

• Real-world evidence research
• Pharmacoepidemiology studies
• Post-authorization safety studies
• Drug utilization research
• Healthcare data analytics

Headquarters

HQ city

Utrecht

HQ country

Netherlands

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Real-World Evidence Research Services: PHARMO generates revenue through commissioned research studies for pharmaceutical companies, regulators, and healthcare organizations. Services include post-authorization safety and efficacy studies (PASS, PAES), drug utilization studies, comparative effectiveness research, and healthcare resource utilization analysis. Revenue is derived from project-based professional services contracts.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

PHARMO Institute delivers real-world evidence research services for the pharmaceutical and healthcare industry, operating linked anonymized Dutch healthcare databases spanning 14 million patients and 250 million person-years. Since 1999, it has provided post-authorization safety and efficacy studies (PASS, PAES), drug utilization studies, comparative effectiveness research with synthetic control arms, and AI-driven patient and disease progression analytics to pharmaceutical companies, regulators, payers, and providers. PHARMO is part of Lumanity and operates as a certified research organization following ENCePP and Good Pharmacovigilance Practice standards.

Product overview

PHARMO Institute is part of Lumanity and operates as a certified research organization that delivers high-quality, real-world research to help the healthcare industry understand how medicines perform beyond the clinical trial setting. Since 1999, they have been analyzing healthcare data to identify side effects earlier, improve patient safety and outcomes, and guide better treatment decisions. Their core services include post-authorization safety and efficacy studies (PASS, PAES), drug utilization studies (DUS), incidence/prevalence/treatment pattern analysis, comparative effectiveness studies with synthetic control arms, healthcare resource use and cost of illness research, and AI-driven patient finding and disease progression analysis. They have direct access to unique Dutch healthcare databases with rich linked data spanning general practitioners, hospitals, clinical laboratories, community and hospital pharmacies, and specialized registries.

Differentiator

Problem solved

Functional benefit

Products and services

• Post-Authorization Safety and Efficacy Studies (PASS, PAES) Tailor-made observational studies that answer complex research questions about the safety, effectiveness, and value of medicines for regulatory and market access purposes. Targeted at pharmaceutical companies and regulatory authorities needing post-marketing evidence.
• Drug Utilization Studies (DUS) Research analyzing how medicines are prescribed, dispensed, and used in real-world clinical practice settings. Used by pharmaceutical companies and regulators to understand treatment patterns.
• Incidence, Prevalence, Treatment Patterns, and Patient Pathways Analysis Epidemiological research examining disease frequency, treatment approaches, and patient journey mapping across multiple healthcare settings. Targeted at pharmaceutical companies, healthcare providers, and payers.
• Comparative Effectiveness Studies with Synthetic Control Arms Studies comparing treatment effectiveness, including the use of synthetic control arms, for regulatory submissions and HTA evidence. Targeted at pharmaceutical companies.
• Healthcare Resource Use and Cost of Illness Research Economic outcomes research measuring healthcare resource utilization and associated costs of diseases. Targeted at healthcare payers and pharmaceutical companies.
• AI-Driven Patient Finding, Classification, and Disease Progression Analysis Advanced analytics using artificial intelligence to identify patients, classify disease states, and analyze disease progression patterns within the PHARMO database network. Targeted at pharmaceutical and research clients needing scalable real-world evidence.
• Multi-Country Pharmacoepidemiologic and Real-World Evidence Studies (via SIGMA Consortium) Single-point coordination for multi-country pharmacoepidemiologic and real-world evidence studies with common protocols and quality-assured delivery, providing access to 10 of the top 15 secondary databases used in European PASS studies. Targeted at pharmaceutical companies needing pan-European evidence.

Quantifiable outcome

• Produced over two decades of peer-reviewed publications across cardiovascular, oncology, metabolic, CNS, and other therapeutic areas

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• SIGMA ConsortiumcoreStrategic or Co-development PartnerPHARMO is a founding member of the SIGMA Consortium, an alliance of European ENCePP research centers providing single-point coordination for multi-country pharmacoepidemiologic and real-world evidence studies. The consortium offers common study protocols and programming, quality-assured delivery, and access to 10 of the top 15 secondary databases used in European PASS studies.
• ENCePP (European Network of Centres for Pharmacoepidemiology and Pharmacovigilance)coreStrategic or Co-development PartnerPHARMO is part of ENCePP, a network of European research centers specializing in pharmacoepidemiology and pharmacovigilance that develops methodological standards and best practices for post-authorization safety studies.
• VAC4EU (Vaccination Alliances and Communities for Europe)minorStrategic or Co-development PartnerPHARMO participates in VAC4EU, a European collaboration focused on vaccine safety and effectiveness research using real-world data.
• EU PPV (European Platform for Pharmacovigilance)minorStrategic or Co-development PartnerPHARMO is part of EU PPV, a European platform dedicated to pharmacovigilance research and post-marketing surveillance.
• LumanitycoreStrategic or Co-development PartnerPHARMO Institute is part of Lumanity, a global health sciences organization that strengthens its real-world evidence capabilities. Lumanity provides the commercial infrastructure and broader service offerings that PHARMO operates within.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/pharmoinstitute
• LinkedInlinkedin.com/company/lumanity

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PHARMO